# persona_off · bixbench · bix-29-q1

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **original**; attempt: **1**.
- Native status: **scored**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied files and any repository documentation only; do not fit the model yet. Report table dimensions, subject identifiers and join cardinalities, treatment labels, missingness, and the observed coding of COVID-related events, severity, medical history, and patient interaction frequency. Check whether the MH spreadsheet duplicates the CSV. Propose a defensible subject-level analysis cohort, COVID-19 ordinal outcome and ordering, prior medical history count definition, interaction-frequency variable and encoding, and exact ordinal regression formula including interactions. Identify any ambiguity in treatment reference, COVID case identification, repeat-event aggregation, absent medical-history records, and which interaction terms the question intends. Explain how the BCG odds ratio will be interpreted if treatment participates in interactions. Return the inspection evidence, proposed approach, and consequential assumptions or uncertainties for review before execution.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The supplied schemas identify demographics, adverse-event, and medical-history tables, but do not establish clinical coding, outcome construction, cohort, or intended interaction structure. These must be inspected before authorizing the ordinal regression.
````

**Objectives Open**

````text
[
  "Inspect inputs and coding relevant to BCG exposure, COVID-19 severity, prior medical history count, and patient interaction frequency.",
  "Agree on cohort, outcome construction, adjustments, interaction formula, and odds-ratio interpretation.",
  "Execute the agreed ordinal regression and retain a reproducible analysis script or notebook.",
  "Provide a concise numerical answer with the required execution payload and analysis artifact path."
]
````

### Event 12 — Actor

**Answer**

````text
Inspection only is complete; no model has been fitted. Approval is requested for the following primary specification.

**Inputs and joins**
- No README, codebook, or analysis repository was supplied: only task.json and the four data files.
- DM: 1,000 × 11; AE: 2,694 × 51; MH: 37,767 × 13. All share exactly the same 1,000 USUBJIDs (500 BCG0… and 500 BCG5… identifiers; range BCG0001–BCG5500). DM is unique by subject; AE has 1–16 rows/subject and MH 34–42. Treatment agrees across every linked record. DM→AE and DM→MH are one-to-many; raw AE→MH is many-to-many and would produce 102,672 rows. Aggregate each independently before joining to DM.
- Treatments are exactly `Placebo` and `BCG`, 500 subjects each. Explicitly set Placebo as reference; automatic alphabetical coding could reverse the reported contrast.
- No exact duplicate rows occur in any CSV. AE nevertheless has 105 repeated (USUBJID,AESPID) keys, including differing dates/severity: these are not safe unique event identifiers.
- MH.xlsx has one sheet, identical dimensions, columns, order, values, and missingness to MH.csv (`DataFrame.equals=True`). Use the CSV once, not both.

**Missingness and observed coding**
- DM has no missing values. `patients_seen`: `1-50`=835, `51-100`=129, `>100`=36. `expect_interact`: Yes=628, No=372. `work_hours`: 1-40=685, 41-80=308, >80=7. Frequency units are not documented.
- AE includes 143 subject-only placeholders with every other field missing, leaving 2,551 populated records. AECAT is RTI=1,020, Other=1,046, ISR=485. AESEV has 1=1,238, 2=741, 3=64, 4=20, missing=631 (488 missing among populated records). AEHS spans 0–7 and is present on all populated records; AEHSFU is missing on 1,673 rows. Onset/weekly health scores are partly strings and include `N_A`. These fields are not interchangeable with AESEV. Clinical labels for numerical severity codes are not supplied.
- COVID case ascertainment proposed from exact AEPT values: COVID-19 (207 rows), COVID-19 pneumonia (9), Asymptomatic COVID-19 (5), SARS-CoV-2 test positive (3): 224 rows, 197 subjects (101 BCG, 96 Placebo). Broad substring searches across hierarchy fields incorrectly add four cardiovascular/chest-pain rows (e.g. matching coronary terms), so will not be used. One COVID-19 row is categorized Other; do not restrict to RTI.
- Among these 197 subjects, 180 have one qualifying row, seven two, and ten three. Some repeated rows share AESPID but differ in date/status. AESEV is missing in 48 qualifying rows; 44 subjects have no observed COVID AESEV. Maximum observed AESEV counts are 1=56, 2=79, 3=11, 4=7. Maximum AEHS instead yields 0=8, 1=64, 2=99, 3=11, 4=5, 5=8, 6=1, 7=1, with no missing subjects. This is a consequential alternative outcome, not an automatic replacement.
- MHSCAT partitions MH into HEALTH QUESTIONNAIRE=6,000 rows, FEMALE REPRODUCTIVE HISTORY=3,520, acute respiratory symptoms=10,000, and MEDICAL HISTORY=18,247. Counting all MH rows would measure questionnaire structure, not disease burden.
- MEDICAL HISTORY has 18 standardized MHTERM entries per subject plus 247 `Other:` entries. MHORRES is 1 on 17,055 rows, 2 on 1,031, missing on 161. Every code-2 row has MHONGO/MHCM details; no code-1 or missing-result row does. All 247 Other entries have code 2. This strongly supports 1=absent, 2=present, although no dictionary explicitly confirms it. MHONGO and MHCM themselves use Yes/No.
- Missing medical-history responses are exclusively Hay fever (81) and Current respiratory tract infection (80), affecting 81 subjects, including 22 COVID subjects. Every subject has an MH assessment, so absent subject-level MH records are not actually an issue here. Missing answers must not silently become absence.
- Across MH, missing MHTEST=18,247; MHORRES=1,654; MHTERM=19,520; MHDECOD=37,328; MHONGO/MHCM=36,736 each. Much is structural, not incomplete assessment. Full per-column missingness is retained in the inspection report.

**Proposed primary analysis**
1. One row per DM subject with at least one qualifying COVID AEPT. This estimates severity among recorded COVID cases, not infection prevention or a population-wide severity/incidence composite. Do not label subjects without a COVID record as uninfected or assign severity zero.
2. Outcome Y = maximum observed AESEV over qualifying COVID records, ordered 1 < 2 < 3 < 4, without inventing clinical labels. Exclude subjects with all COVID AESEV missing. Use observed maximum when some records are missing, explicitly acknowledging possible underestimation. Worst observed severity avoids treating repeats as independent observations; first-event or longitudinal aggregation would estimate a different outcome.
3. H = count of positive (`MHORRES==2`) MHTERM entries within baseline `MHSCAT=='MEDICAL HISTORY'`, including Other entries and both ongoing and resolved histories. No subject-term duplicates occur. Exclude health-questionnaire, reproductive, and symptom-screen rows; do not count MHDECOD nonmissingness as history. Set H missing if any standardized history answer is missing; primary complete-case analysis avoids conflating unknown with negative. A zero count is justified only for a completed assessment with no positives. This definition includes baseline current RTI as a recorded history item rather than retrospectively changing the checklist.
4. P = categorical `patients_seen`, reference `1-50`, with indicators for `51-100` and `>100`. Avoid assuming equal distances or a midpoint for the open-ended bin. `expect_interact` measures anticipated contact, not frequency, and is not the primary adjustment.
5. T=1 for BCG, 0 for Placebo. Fit proportional-odds cumulative logistic regression with all pairwise interactions, no three-way interaction:
   `Y ~ T + H + C(P) + T:H + T:C(P) + H:C(P)`.
   Specifically, logit Pr(Y>k) = η − θ_k, k=1,2,3, where η = βT T + βH H + βP1 P1 + βP2 P2 + βTH TH + βTP1 TP1 + βTP2 TP2 + βHP1 HP1 + βHP2 HP2. Ordered thresholds replace a separate intercept; H is uncentered.
6. These choices yield 141 complete subjects: BCG 71 (severity counts 26,32,8,5), Placebo 70 (23,42,3,2). Frequency groups are 99,33,9. Check rank, convergence, Hessian/SEs, sparsity/separation, and proportional-odds plausibility before reporting estimates. Do not silently simplify interactions if unstable.

**Odds-ratio interpretation and requested decisions**
With treatment interactions there is no single covariate-invariant BCG OR. The conditional higher-severity OR is exp(βT + βTH H + βTP1 P1 + βTP2 P2). exp(βT) is BCG versus Placebo only at H=0 and patients_seen=1-50, common across outcome thresholds under proportional odds. OR>1 means greater odds of worse severity. I propose reporting that explicitly qualified reference-profile OR with a 95% CI, plus the conditional formula; it is not a marginal population effect.

The question does not identify which interactions are intended. My default uses all pairwise interactions among its three predictors. `T*H*C(P)` would additionally include the three-way term; `T + H*C(P)` would interact only adjustment variables and yield a constant treatment OR. These are substantively different models. Likewise, AEHS rather than AESEV, COVID-19 alone rather than the four-term case definition, a no-COVID outcome category, ignoring missing MH responses when counting positives, or numeric frequency coding would materially change the answer. Please approve the primary choices above or specify replacements before fitting.
````

**Stage**

````text
plan
````

**Evidence**

````text
Executed inspection/inspect_inputs.py and inspection/focused.py; saved full schema/missingness/join/coding results in inspection/report.txt and inspection/focused_report.txt. Spreadsheet equality is exact after pandas import. Additional inspection counted the proposed 141-person complete-case cohort and treatment-by-severity cells; no regression, coefficient estimation, or OR calculation was performed.
````

**Assumptions**

````text
[
  "Higher numeric AESEV denotes worse severity; clinical category names are undocumented.",
  "MHORRES=2 denotes present and 1 absent, supported by the presence of condition details.",
  "All pairwise interactions are the proposed interpretation of 'interaction between terms', pending approval.",
  "Complete-case MH handling and case-only severity define the primary estimand; selection and missingness can bias comparisons."
]
````

**Uncertainties**

````text
[
  "No codebook confirms severity labels or distinguishes the intended AESEV versus AEHS outcome.",
  "No supplied testing adjudication confirms that every recorded COVID AEPT represents a laboratory-confirmed case.",
  "Worst observed repeat-record severity and missing-value handling are analytical choices.",
  "Only nine proposed complete cases are in the highest frequency group; treatment interactions may be imprecise or unstable.",
  "Conditioning on post-treatment COVID case status precludes an unqualified causal vaccine-effect interpretation."
]
````

### Event 13 — Simulator

**Message**

````text
Approve the proposed primary specification for execution: case-only maximum observed AESEV, complete-case history count using positive MEDICAL HISTORY entries, categorical patients_seen, Placebo reference, and all pairwise interactions without a three-way term. These are defensible analytical assumptions, not confirmed source intent. Fit the stated proportional-odds model and retain an executable analysis script or notebook. Verify baseline status of the history records from available visit fields, and report any contradiction before interpreting H as prior history. Report the actual analytic cohort, design rank, convergence, finite standard errors/Hessian diagnostics, sparse cells, and an appropriately cautious proportional-odds assessment; do not silently remove interactions. Give the reference-profile BCG higher-severity odds ratio exp(beta_T), 95% CI, and the conditional OR formula with fitted coefficients, clearly stating H=0 and patients_seen=1-50 and whether that profile is represented. Briefly flag case-selection, missingness, and undocumented coding limitations. If the primary fit is estimable, no broad alternative-model search is necessary. Return a concise candidate answer plus diagnostic evidence, payload.executed_analysis=true only after execution, and artifacts.analysis pointing to the executed script or notebook.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports independent subject-level aggregation is necessary, exact MH spreadsheet duplication, explicit BCG/Placebo labels, structurally heterogeneous MH records, and a proposed 141-person complete-case cohort. The proposed formula addresses all named predictors and interactions while correctly recognizing that treatment interactions imply conditional rather than constant BCG odds ratios. Source coding and interaction intent remain assumptions.
````

**Objectives Open**

````text
[
  "Execute the agreed ordinal regression and assess estimability and diagnostics.",
  "Report the qualified BCG odds ratio and confidence interval with conditional interpretation.",
  "Provide the concise final answer and executed analysis artifact required by the submission contract."
]
````

### Event 16 — Actor

**Answer**

````text
Candidate answer: In the approved subject-level proportional-odds model (141 recorded COVID cases), the BCG-versus-Placebo odds ratio for higher COVID-19 severity was **1.18 (95% Wald CI 0.41–3.41)** at **zero positive baseline medical-history entries and patients_seen=1–50**. The model included history count, categorical patient-interaction frequency, and all pairwise interactions. Because treatment participates in interactions, this is a reference-profile OR, not a single overall vaccine effect; the estimate is imprecise and the interval includes 1.

The fitted conditional OR is:
OR_BCG(H,P) = exp[0.166390 − 0.073019 H + 0.010988 I(P=51–100) + 1.387018 I(P=>100)],
with coefficient rounding; exact coefficients are retained in analysis/parameters.csv. OR>1 denotes higher odds of worse severity at each cumulative threshold under proportional odds. The reference profile is observed in 29 subjects (12 BCG, 17 Placebo).

History timing: all 18,247 MEDICAL HISTORY records and all 1,000 DM records carry `Screening-Day -3 to 1`. This supports a baseline screening assessment, with no contradictory follow-up visit labels. However, the window extends to day +1, and no individual history-onset or vaccination timestamps establish strict pre-vaccination timing. H is therefore best described as a baseline recorded-history count, not a verified count of conditions predating vaccination.

Limitations: this is a case-selected association, not an unconditional causal vaccine effect. Missing severity/history responses can bias complete-case results. Numerical severity ordering and history-positive coding lack a supplied codebook. Sparse data impede checking proportional odds; it must remain an unverified assumption.
````

**Stage**

````text
result
````

**Evidence**

````text
Executed analysis/solution.py successfully. Primary fit retained every approved term: T + H + P1 + P2 + T:H + T:P1 + T:P2 + H:P1 + H:P2, with three ordered thresholds, logistic link, and Placebo reference. COVID cases used the four approved exact AEPT values and maximum observed AESEV ordered 1<2<3<4. Of 197 recorded cases, 44 lacked all qualifying AESEV values; a further 12 with observed severity had incomplete history responses, yielding 141 subjects (BCG=71; Placebo=70). Severity counts by arm: BCG=[26,32,8,5]; Placebo=[23,42,3,2].

Design matrix has 9 columns and rank 9; adding a constant gives rank 10. BFGS converged with warnflag=0, 62 function/gradient evaluations, log likelihood −143.3244, and maximum absolute score 1.88e−7. All 12 parameter standard errors are finite. The observed-information eigenvalues are all positive (min 0.30838, max 217.20581; condition number 704.35). The treatment log-OR is approximately 0.166390 with SE 0.541385; exp(beta_T)=1.1810332 and the 95% Wald CI is [0.4086681,3.4131354]. Primary estimation is numerically estimable; no interaction was removed.

Sparse cells (severity 1,2,3,4): BCG/1–50=[21,23,8,3]; BCG/51–100=[5,6,0,1]; BCG/>100=[0,3,0,1]; Placebo/1–50=[14,26,2,2]; Placebo/51–100=[8,13,0,0]; Placebo/>100=[1,3,1,0]. Only nine participants are in >100, 18 have severity>2, and seven have severity>3. At the reference profile, BCG outcomes=[4,7,1,0] and Placebo=[8,9,0,0].

Proportional-odds assessment: diagnostic separate binary logits at the three cumulative cutoffs retained the same design. Cutoffs 1 and 3 produced singular-Hessian failures; cutoff 2 failed to converge and had coefficients as large as 30.6, consistent with severe sparsity/separation. These diagnostic fits are not alternative primary models and cannot support a trustworthy slope-equality test. Descriptive calibration also warrants caution: observed vs fitted Pr(Y>2) was 0.071 vs 0.118 in Placebo and 0.183 vs 0.137 in BCG. This is not a formal rejection, but neither is proportional odds validated. No broad alternative-model search was performed.
````

**Assumptions**

````text
[
  "Increasing AESEV codes represent increasing severity; MHORRES=2 is positive history.",
  "Maximum observed COVID AESEV represents subject-level severity even when another qualifying event has missing severity.",
  "History count includes all positive MEDICAL HISTORY terms, including baseline current RTI and Other entries; missing checklist responses cause exclusion.",
  "All pairwise interactions without a three-way term reflect the approved analytical specification, not confirmed original source intent."
]
````

**Uncertainties**

````text
[
  "Proportional odds could not be reliably tested with the sparse full-interaction design.",
  "Baseline visit labels support screening history but do not prove strictly pre-vaccination onset/timing.",
  "Complete-case and post-treatment case selection limit causal interpretation and generalizability.",
  "Rare severe outcomes and sparse frequency strata make the Wald interval and conditional effects uncertain."
]
````

### Event 17 — Simulator

**Message**

````text
The reported analysis adequately answers the question under the agreed specification. Final answer: The BCG-versus-Placebo odds ratio for higher COVID-19 severity was 1.18 (95% CI 0.41–3.41) at zero baseline medical-history entries and patients_seen=1–50, from the ordinal logistic model of 141 recorded COVID cases adjusting for history count, categorical interaction frequency, and all pairwise interactions. Because BCG interacts with the covariates, this is a reference-profile rather than an overall odds ratio. Sparse data leave proportional odds unverified, and the case-selected estimate should not be interpreted as an unconditional causal vaccine effect. Retain payload.executed_analysis=true and artifacts.analysis='analysis/solution.py' in the final submission.
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The agent reports successful execution of the approved full-interaction model, full design rank, convergence, positive observed-information eigenvalues, and finite standard errors. The reported treatment coefficient 0.166390 and SE 0.541385 support the stated OR and interval. Cohort exclusions, reference-profile support, baseline timing uncertainty, and unsuccessful sparse-data proportional-odds diagnostics are disclosed. The executed script path and required execution flag are supplied.
````

**Objectives Open**

````text
[]
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/openai-astra-top2-first-pass/episodes/bixbench_bix-29-q1-10c2db1c014a/persona_off/attempt-1/output/bixbench_bix-29-q1-10c2db1c014a/controller/events.jsonl",
  "event_log_sha256": "cf7adb19043ebb74b9e64d6ed52538dcccac4f16fce7e8fc97033d9532807f76",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
